UBS explores China’s accelerating push into biotechnology and how it is shifting from cost-based manufacturing toward scaled drug innovation. The paper highlights China’s emergence as a global dealmaking force, with growing outbound licensing activity and faster clinical timelines. It also questions whether this speed-driven model can produce true first-in-class breakthroughs.
China’s Biotech Revolution
UBS
Min Lan Tan
Research
33 Pages
Key Takeaways
Clinical Speed Advantage: China reduces clinical trial timelines by 30–50% versus the US, enabling faster progression from Phase I to approval and attracting global pharma partnerships.
Licensing Deal Growth: China’s share of global biotech licensing rose from under 10% in 2017 to about 33% in 2024, reflecting a rapid shift in innovation sourcing.
R&D Investment Scale: National R&D spending reached RMB 3.6 trillion, with roughly RMB 430 billion directed toward life sciences, supporting long-term biotech ecosystem expansion.
Join our newsletter to have all of this content + Exclusive Newsletter Bonus Content delivered to your inbox every week
